






Surgery rapidly induces remission in Crohn’s disease (CD) but patterns of clinical recurrence and healthcare utilization beyond 1 year have not been well characterized.  CD is one of the most significant chronic gastrointestinal condition, that is associated with high morbidity and decreased quality of life. From a 2002 population based study Crohn's disease was found to affect about 400,000- 600,000 people in North America causing a significant public health burden and associated healthcare cost. 
Methods
Retrospective observational study of CD patients undergoing resection/anastomosis stratified by patterns of healthcare utilization during the two year follow-up: High Utilizer (HU) group  who require CD related emergency department visit (ED), hospital admission (HA) or repeat bowel surgery (RS) in the 2 year post-operative period and Low Utilizer (LU) group who have none of these events.
Results
There were 45 CD patients with resection and side-to-side anastomosis (49% males, age 40.5 years, 24.4% smokers, 33.3% previous resection, 62.2% laparoscopic). Within 2 years of surgery, 46.7% required abdominal CT scan (78 scans, 21 patients), 33.3% required ED evaluation (70 ED visits, 15 patients), 29% had HA (40 HA, 13 patients) and 6.7% had RS (3 surgeries, 3 patients). There were differences between the LU (N=30) and HU groups (N=15) in the rate of smoking (13% vs. 26%; p=0.02), presence of > 2 co-morbid medical conditions (3.3% vs. 46.7%; p=0.001), biologic use before surgery (23% vs. 60%; p=0.009), biologic use after surgery (13% vs. 47%; p=0.026) and post-operative steroid use ( 10% vs. 53%;p= 0.003). Inflammation on post-operative colonoscopy was identified in 24 % of patients (20% vs. 33%; p=0.4).
Conclusions
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Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract resulting in cumulative damage, remodeling, stricturing and a need for resective intestinal surgery in the majority of patients ().  Surgery with anastomosis is not curative and the disease returns in the majority of patients, typically at the anastomotic site and half of these individuals will require repeat surgery due to complications of disease recurrence during their lifetime  ADDIN EN.CITE (, ). Prior studies performed over the past 2 decades evaluating disease recurrence based on objective assessment (i.e. colonoscopy, radiologic assessment) have suggested twice the rate of inflammation recurrence compared to patterns of clinical or symptomatic recurrence, but these studies were performed without post-operative medical treatment in an era of handsewn anastomosis  ADDIN EN.CITE (, ).
The use of immunomodulators and anti-TNF biologic agents has helped majority of patients to achieve and maintain remission  ADDIN EN.CITE (). New protocols advocating post-operative maintenance therapy following resection have demonstrated high rates of endoscopic remission 1 year after surgery  ADDIN EN.CITE (). What is unknown is how patients will manifest abdominal symptoms following a surgically induced remission in the present era of routine post-operative immunomodulator and biologic maintenance therapy. In a landmark study, Rutgeerts et al. characterized the natural history of untreated post-operative CD, demonstrating that 70% of patients with ileocolonic resection showed mucosal recurrence at one year, while clinical recurrence was much lower, at only 10-15% (). In addition to medical advances, CD surgical treatment has also evolved during this time period. Expert centers have embraced laparoscopic approaches, as well as use of compression stapled anastomosis replacing hand-sewn anastomosis  ADDIN EN.CITE (, ). There is limited data describing the patterns of CD post-operative recurrence and health care utilization in the present era of immunomodulator/biologic therapy and the correlation of post-op symptoms with recurrent inflammation. 





2.1.1	Study design and population
This was a retrospective observational study in a tertiary care referral center. After institutional review board approval, clinical data from January 1, 2008 through December 31, 2010 were retrospectively reviewed by using the institutional medical archive system (). All subjects were older than 18 years of age and underwent bowel reconstruction with stapled side-to-side anastomosis in 2008 with 2 years of follow-up. Subjects were initially identified by means of procedure codes, and then clinical data was retrieved and reviewed by the authors. All data were de-identified prior to analysis by using an institutional honest broker system.  All data were collected and reviewed in compliance with the Health Insurance Portability and Accountability Act. Clinical information reviewed included operative report, admission notes, discharge summaries, emergency department records, imaging, and endoscopy reports.    
2.1.2	Variables
Data extracted included: gender, age at the time of surgery, age at diagnosis, disease behavior, location, indication for surgery, history of previous resection, family history, smoking, drug allergies, history of depression,  co-morbid medical conditions, chronic narcotic use, immunomodulator (i.e. azathioprine, 6-mercaptopurine, methotrexate) use at the time of admission, immunomodulator use at discharge, biologic treatment (i.e. infliximab, adalimumab, certolizumab pegol) at admission, biologic treatment at discharge, complex resection, surgical approach, and part of bowel resected.
2.1.3	Healthcare utilization during the post-operative time period: Clinical events
Five categories of clinical events/procedures were measured during the post-operative time period  including: (i) Emergency Department (ED) visits; (ii) Hospital Admissions (HA); (iii) Repeat Bowel Surgery (RS); (iv) Colonoscopies (COL); (v) Abdominal Pelvic CT (CT) scans  ADDIN EN.CITE (). All clinical events were evaluated, but only data relevant for CD intestinal symptoms/exacerbation were included in the analysis (i.e. abdominal pain, bloody stool, obstructive symptoms or perianal symptoms, etc.). Healthcare utilization not related to CD were not included or analyzed in this project (i.e. obstetrical care, trauma, etc.). The suspicion of CD exacerbation was based on the assessment of the treating physician as recorded in the medical record, and this formed the basis for event inclusion/exclusion.  All CD surgical interventions including abdominal procedures and abscess drainage were analyzed. 
2.1.4	Definition of post-operative CD clinical outcome groups: High and Low Utilizer groups
The post-operative CD cohort was stratified based on patterns of healthcare utilization during the two years following surgery/anastomosis: High Utilizer (HU) and Low Utilizer (LU) groups. Patients who required an emergency department (ED) visit, hospital admission (HA) or repeat bowel surgery (RS) related to CD in the 2 year post-operative time period were classified as HU group, while patients with none of these events were designated LU group. Behavior and location of CD was classified according to the Montreal classification. Complex resection was defined as surgery involving more than 1 resection, fistula repair or abscess debridement. In the colonoscopy procedure reports, evidence of inflammation was reported using the modified Rutgeert’s score which was prospectively recorded at the time of the procedure(). Rutgeerts score of i0 or i1 were graded as mild post-operative inflammation and Rutgeerts score of i2, i3 or i4 were categorized as moderate – severe post-operative inflammation and counted as endoscopic recurrence.  During review of the CT reports, any mention of bowel inflammation, obstruction, abscess or perforation was counted as an “acute process” (). 
2.1.5	Statistical analysis
Descriptive statistics were performed using the Chi-square and Fisher’s exact tests for proportions. Continuous variables were expressed as means with standard deviation. Univariate analysis of the continuous variables were performed using the independent Student T test for normal distribution and using two tailed Mann Whitney U Test for non-parametric distribution.  In our primary analysis, a univariate analysis was performed to examine the association between study variables and HU group (i.e., ED visits, HA and/or RS) among all CD patients who underwent bowel resection surgery.  Statistical analysis was performed using IBM SPSS software (SPSS Statistics 17.0, Inc., and Chicago, IL, USA).

3.0 	RESULts
3.1.1	Post-surgical CD patients: Demographic information
A total of 45 patients who underwent bowel resection with anastomosis in 2008 and had 2 year follow-up comprised the study population (Table 1). Mean age was 40.5 + 13.2 years (mean + SD), CD duration at the time of surgery was 10.0 + 10.3 years (mean + SD), 49% were males, 42.2% had penetrating disease, 33.3% had a history of prior bowel resection, 17.8% had a family history of inflammatory bowel disease (IBD) and 24.4% were active smokers at the time of surgery in 2008. The anatomic disease distribution was ileal in 60% followed by Ileocolonic location in 35.6% of the patients.
3.1.2	Co-morbid illness in post-operative CD patients
During the two year post-operative time period, 24.4% of the CD patients required narcotic use due to abdominal pain and 37.8% of the patients were on antidepressant medications. Additional co-morbid illness was identified in 17.8% of the post-operative patients who had more than two co-morbid medical conditions.
3.1.3	Outcome Groups: LU and HU
The LU (N=30) and HU (N=15) post-operative groups were similar with respect to mean age at surgery (39.4 vs. 42.6 years; p = 0.75), duration of CD at the time of surgery (10.3 vs. 10.2 years; p = 0.36), gender (males 46.6% vs. 53.3%; p = 0.75), penetrating disease behavior (46.7% vs. 33.3%, p = 0.53) , anatomic location of disease (Ileal 60% in both, Ileocolonic 33.3 % vs. 40%; p = 0.88) and use of laproscopic surgical approach (63.3% vs. 60% ; p= 0.90). The HU group had more patients with a history of prior surgical resection (53.3%) compared with the LU group (23.3%) but this difference did not reach statistical significance (p = 0.09). A high percentage of patients with depression were identified in our study, where 30% in the LU group and 53.3% in the HU group were being treated for this condition (p = 0.19).
Clinical variables which differed between the LU and HU groups included active smoking (13.3 % vs. 46.6%; p = 0.02), presence of more than two co-morbid medical conditions (3.3% vs. 46.7%; p = 0.001) and chronic narcotic use (10% vs. 53.3%; p = 0.003). Previous studies have already shown that smoking and narcotic use are associated with severe disease, whereas comorbidities significantly increased the health care use in CD patients  ADDIN EN.CITE (). Even though there is a difference in the rate of smoking between the two groups, there was no difference in the rates of inflammation. The mean post-operative length of stay was longer in the HU group when compared with the LU group (10.5 vs. 5.6 days; p = 0.004). The factors responsible for longer length of stay in the HU group include postoperative ileus, fever, pulmonary embolism and surgical wound infection.
3.1.4	Post-operative medications for CD prophylaxis
We defined early post-operative prophylaxis as initiating either immunomodulators and/or biologics within 4 weeks of surgery. In our entire cohort 55.5% of the patients (25/45) were initiated on early post-op medical prophylaxis within one month after the surgical resection. During the two year follow-up period an additional 20% of the patients (9/45) were started on immunomodulator/biologic therapy, primarily in response to the disease activity (Figure 1). Therefore, 75.5% of our post-operative CD patients were receiving immunomodulator and/or biologic therapy at the 2 year post-operative time period (LU 70% vs. HU 86%; p = 0.2). In the patients who were not started on early post-op medical prophylaxis, 30% of patients ended up in the HU group (n = 6/20), similarly 36% of the patients who were started on early postop prophylaxis ended up in the HU group (n = 9/25; p=NS). Between the LU and the HU groups, we found significant difference in the use of biologics at admission before surgery (23% vs. 60%; p=0.009), use of post-operative biologics (13% vs. 46%; p=0.02) and post-operative steroid use (10% vs. 53%; p= 0.003).
3.1.5	Post-operative healthcare utilization patterns 
Table 2 outlines the 2 year patterns of healthcare utilization in the post-operative CD patients. In the post-operative period, 46.7% of the patients underwent abdominal CT scans (Figure 3), 33.3% of the patient’s required ED evaluation (Figure 4), 28.9% required HA (Figure 5) and 7% had repeat bowel resections (Figure 6). However, the cumulative number of clinical events in the HU group was remarkable. The 15 individuals who required ED evaluation made a total of 70 ED visits over the 2 year time period. The 13 patients who required hospital admission accounted for a total of 40 hospitalizations over 2 years. There were 3 patients who required repeat bowel resections within 2 years of the 2008 operation. When we consider patterns of abdominal CT imaging in the post-operative setting, there were 21 patients who had a total of 78 CT scans during the 2 year observation time period. The CD patients in the LU group contributed to 14 CT scans while the patients in HU group were responsible for 64 scans. 
Next we evaluated the interval between surgery and these clinical events. The mean number of days following surgery to ED evaluation was 255; to hospitalization was 233 and to repeat bowel resection was 424. The mean number of days to the first post-operative CT scan was 320 days.  We further analyzed the clinical factors contributing to the events which defined the HU group. Male patients accounted for 80% of the total ED visits (56/70), 60% of total hospitalizations (24/40) and 75.6 % of total CT scans (59/78). Colonoscopic evidence of inflammation was found in 24 % (11/45) of the patients in the entire cohort (6 patients in the LU and 5 patients in the HU group). Among the 78 CT scans, acute process was identified in 27% of the scans (21/78).
3.1.6	Post-operative bowel inflammation detected by colonoscopy
In our postoperative cohort, all the patients had colonoscopy performed within 2 years of surgery, with a mean time of first colonoscopy at 11 months.  We did not see clear correlation between mucosal changes and clinical outcomes in our patients. In the entire cohort, neo-terminal ileum inflammation on post-operative colonoscopy was identified in 24% of patients (Figure 2). Only 33% of the patients in the HU group (5/15) demonstrated objective evidence of mucosal inflammation in the neo-terminal ileum, despite the fact that all of these individuals required evaluation for active CD symptoms. Similarly, when we considered the endoscopic assessment of the LU group patients in the 2 year post-operative period, there were 20% (6/30) who had significant inflammation at the neo-terminal ileum. There were no significant difference in bowel inflammation between the LU and HU groups (p = 0.4) at the 2 year post-operative time period.
4.0 	discussion
CD is associated with high morbidity, decreased quality of life and high economic burden  ADDIN EN.CITE (, ). One third of the direct costs in CD care are attributable to hospitalization  ADDIN EN.CITE (). We hypothesized that there is a group of patients in the post-operative time period who over-utilize healthcare resources without objective evidence of bowel inflammation. In this study we describe the pattern of healthcare utilization in a cohort of post-operative CD patients followed at a tertiary center in the present era of laparoscopic surgery with stapled side-to-side anastomosis and immunomodulator/biologic therapy. In our cohort, we identified that 33% of the post-operative CD patients experienced significant clinical symptoms and required ED utilization (HU group). These patients in the HU group were responsible for 70 ED visits, 40 hospitalizations and 3 surgical resections in the 2 year post-operative period.
The study results suggest a heterogeneous pattern of clinical recurrence in post-operative CD patients following side-to-side anastomosis, where 22% ( 10 out of 45 patients) of patients developed significant functional symptoms in the absence of objective gut inflammation while an additional subgroup (24.4%, 11 out of 45 patients) developed severe/refractory inflammatory disease despite best efforts to control recurrence. Out of these 11 individuals, only 5 belonged to the HU group (45% of patients with objective evidence of inflammation) and they contributed to 25 ED visits (25/70, 36%), 23 Hospitalizations (23/ 40, 57%), 21 CT scans (21/78, 27%) including all 3 repeat surgical resections. These data suggest that two-thirds of postoperative CD patients who required an ED visit did not have an objective evidence of inflammation on colonoscopy.  In marked contrast the majority of patients with endoscopic recurrence (6/11, 55%) did not warrant an ED evaluation and/or hospitalization during the two year post-operative time period.  There were a total of 78 CT scans performed among 21 patients from both groups. The patients in the HU group were responsible for a disproportionate number of CT radiologic studies, the majority of which did not demonstrate any acute process. The HU group also includes a subgroup of severely ill patients (N=3) who required repeat abdominal surgery within 2 years of a prior surgery (7% of the post-operative patients). All of these rapid-abdominal reoperation patients failed attempts at post-operative medical therapy.
A number of studies have evaluated the natural history of post-operative CD recurrence  ADDIN EN.CITE (, , , ). In the pre-immunomodulator/biologic era, Rutgeerts et al. demonstrated that within 6 years of terminal ileal resection/anastomosis, over 90% of CD patients demonstrated objective evidence of inflammation at the neo-terminal ileum(). In marked contrast, symptomatic recurrence was only seen in 60% of CD patients by the 6 year time period. This study was carried out > 20 years ago, when immunomodulators were not routinely used in CD management, no biologic agents were available and no post-operative maintenance therapy was routinely employed. McCleod and colleagues characterized the patterns of clinical (i.e. symptomatic recurrence) and objective recurrence of inflammation (i.e. endoscopic/radiologic recurrence) in a landmark study published in 1997 ADDIN EN.CITE (). In this study, the post-operative endoscopic / radiologic recurrence was 60 % at 2 years in the CD patients who underwent bowel resection with anastomosis, while the clinical/symptomatic recurrence was approximately 40% at the same time period. Our study, which reflects a very different era emphasizing  the use of maintenance immunomodulator/biologic agents in the majority of post-operative CD patients, yielded strikingly different results with 24.4% showing objective endoscopic recurrence of CD, while close to half experienced abdominal symptoms (47%)  requiring CT scan for symptoms and 33% requiring ED evaluation for CD related symptoms.
Use of narcotics has substantially increased in the IBD population  ADDIN EN.CITE (, ). Cross and colleagues demonstrated that outpatient narcotics were associated with decreased quality of life in CD  ADDIN EN.CITE ().  Long et al. showed that narcotics were used in 70% of IBD inpatients and narcotic use was not associated with disease severity based on the CT imaging or endoscopy(). In our study we saw high rates of narcotic use (24%) which was higher than previous reports in IBD patients (5-13%), and we suspect that this may reflect the challenges encountered by post-operative patients and increased functional symptoms found in this group. The HU group in our study had higher rates of narcotic use when compared with the LU group (53% vs. 10%, p = 0.003). The specific relationship between narcotic use and high healthcare utilization were not defined, but we can hypothesize that narcotics may exert negative side effects which can include worse bowel motility in post-operative patients who may be more predisposed to bacterial overgrowth and transmission of colonic pressure into the small intestine (“common cavity effect”) following loss of the ileocecal valve  ADDIN EN.CITE (, ). 
In 2005 health care expenses was nearly $2 trillion, accounting for over 16 % of the United States gross domestic product, compared to 6.5 % in 1990's  ADDIN EN.CITE (). The sustained increase in U.S. health spending over the last five decades is likely to continue, and total health care spending is projected to reach $4 trillion (20% of GDP) by 2015. Much of this growth is primarily attributed to the increasing prevalence of chronic medical conditions for which direct treatment costs alone are estimated to be $277 billion annually (). CD is one of the most significant chronic gastrointestinal condition that is associated with high morbidity  ADDIN EN.CITE () and decreased quality of life (). From a 2002 population based study Crohn's disease was found to affect about 400,000- 600,000 people in North America causing a significant public health burden and associated healthcare cost  ADDIN EN.CITE (). The findings reinforce the need for effective treatment strategies to reduce IBD complications and related healthcare cost.
There are several important strengths and limitations in our study. We used an honest broker to identify all patients which limited the potential for selection bias within our population. However, there were important weaknesses. The retrospective design, single-center site, referral bias and small study size all could have prevented our findings from being generalizable.  We attempted to counterbalance some of these issues by focusing on clinical outcomes which were more objective, specifically patterns of healthcare utilization with ED, HA, CT and RS. Additional work in other centers will be needed to determine if our findings are relevant to the general CD population.

5.0 	conclusion 





























All these patients had moderate – severe inflammation on the colonoscopy.
Figure 7. Timeline of the repeat bowel resection in the 2 year follow up period ( N=3).
Appendix B: TABLES
Table 1. Descriptive demographics. 

Variable	Entire cohort (n=45) 	Low Utilizer group (n=30)	High Utilizer group (n=15)	P value
Mean age at the time of surgery (years, SD)	40.5 (13.2)	39.4 (13.8)	42.6 (12)	0.75
Mean age of Crohn’s diagnosis(years, SD) 	30.3 (13.8)	30.2 (14.0)	30.6 (13.9)	0.69
Duration of Crohn’s disease (years, SD) 	10.0 ( 10.3) 	9.0 ( 10.3) 	12.0 ( 10.2) 	0.36
Gender	Male 48.9%	Males 46.6%	Male 53.3%	0.75
Race	White 95.6%	White 96.7%	Whites 93.3%	0.56
Penetrating Behavior 	19 (42.2%)	14 (46.7%)	5(33.3 %)	0.536
LocationL1 ( Ileal)L2 ( colonic)L3( Ileocolonic)	27 (60%)2 (4.4%)16 (35.6%)	18(60 %)2(6.7 %)10 (33.3 %)	9(60 %)0(0%)6 (40 %)	0.881
IndicationResistant to medical treatmentFibro-stenosingFistula / abscessNeoplasticTakedown of diverting ostomy	4 (8.9%)23 (51.1%)15 (33.3%)2 (4.4%)1 (2.2%)	3 (10 %)12 (40 %)12 (40 %)2 (6.7 %)1 (3.3 %)	1(6.7%)11 (73.3%)3 (20 %)0 (0%)0 (0%)	0.315
History of prior resection	15 (33.3%)	7 (23.3 %)	8 (53.3 %)	0.09
Family History of IBD	8 (17.8%)	4 (13.3 %)	4 (26.7 %)	0.41
Active smoking 	11 (24.4 %)	4 (13.33%)	7 (46.66%)	0.026*
NSAID use post-op	1 (2.2%)	0	1 (6.7%)	0.33
Drug allergies	21 (46.7%)	11 (36.7 %)	10 (66.7 %)	0.112
History of Depression	17 (37.8%)	9 (30 %)	8 (53.3 %)	0.193
More than 2 co-morbid medical conditions #	8 (17.8%)	1 (3.3%)	7 (46.7%)	0.001*
Chronic narcotic use	11 (24.4%)	3 (10%)	8 (53.3%)	0.003*
Immunomodulator use at admission	13 (28.9%)	10 (33.3%)	3 (20%)	0.49
Immunomodulator use at discharge	14 (31.1%)	12 (40%)	2 (13.3%)	0.09
Biologic use at admission (infliximab, certolizumab pegol, adalimumab)	16 (35.6%)	7 (23.3%)	9 (60%)	0.009*
Biologic use at discharge (infliximab, certolizumab pegol, adalimumab)	11 (24.4%)	4 (13.3%)	7 (46.7%)	0.026*
Steroid use at admission	13 (28.9%)	8 (26.7%)	5 (33%)	0.73
Steroid use in post-op period 	11 (24.4%)	3 (10%)	8 (53%)	0.003*
Complex resection	18 (40%)	13 (43.3 %)	5 (33.3%)	0.74
Surgical approachLaproscopicLap converted to openExploratory laprotomy	28 (62.2%)10 (22.2%)7 (15.6%)	19 (63.3%)6 (20%)5 (16.7%)	9 (60%)4 (26.7%)2 (13.3%)	0.90
Anatomic resectionSmall intestine onlyLarge intestine onlyBoth small and large intestine	11 (24.4%)2 (4.4%)32 (71.1%)	5 (16.7%)2 (6.7%)23 (76.7%)	6 (40%)0 (0%)9 (60%)	0.23
Mean length of stay in days (SD)	7.2 (6.5)	5.6 (2.0)	10.5 (10.4)	0.004*
Patients who required an emergency department (ED) visit, hospital admission (HA) or repeat bowel surgery (RS) related to CD in the 2 year post-operative time period were classified as HU group, while patients with none of these events were designated LU group.




Table 2. Descriptive Patterns of healthcare utilization.
Healthcare utilization related to CD symptoms  	Percentage of patients (number of patients/total cohort)	Cumulative  number of events	Occurrence of first event from the time of surgery in days (mean + SEM)
ED visit	33.3% (15/45)	70	255.7 + 59.3
Hospital admission	28.9% (13/45)	40 	232.8 + 59.8 
Surgery Total proceduresRepeat surgical resection	17.8% (8/45)6.7% (3/45)	14 3 	416.3  + 56.8 424.3  + 91.8
CT scan of abdomen	46.7% (21/45)	78	319.7 + 46.3
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Black circles indicate studies with evidence of acute process on the CT scan
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